Health Yuan's innovative foundation: TG-1000 is about to be launched, achieving stable operation in the first quarter of 2024
Published Time:
2024-04-26
On the evening of April 25, 2024, HealthGen (600380.SH), a leading respiratory drug manufacturer, disclosed its first-quarter performance.
In the first quarter of 2024 (January-March), the company achieved operating revenue of 4.34 billion yuan and net profit attributable to shareholders of 440 million yuan. Sales of the company's key products in the respiratory specialty field significantly contributed to overall revenue, reaching 417 million yuan in the first quarter, accounting for 9.61% of total revenue.
While maintaining robust operating performance, HealthGen's key innovative drug products have also achieved breakthrough progress. An announcement on April 17 showed that the multicenter Phase III clinical trial of its influenza drug TG-1000 capsules for the treatment of uncomplicated influenza A and B acute infections in patients aged 12 and above without complications has met its primary endpoint and will soon submit a listing application to the CDE (Center for Drug Evaluation).
Since last year, the competitive landscape of the pharmaceutical industry has become increasingly complex, and the innovative growth and resilient development of pharmaceutical companies have been repeatedly tested. Under the dual-engine strategy of innovative drugs and high-barrier complex preparations, HealthGen uses innovation and internationalization as its development framework to promote the company's sustainable development. Relevant data analysis, From 2009 to 2023, HealthGen's operating revenue achieved a compound annual growth rate of 10.58%.
Inhalation preparation pipeline continues to perform strongly Accelerated progress in innovative drug R&D layout
HealthGen has always adhered to R&D-driven development, differentiated layout of innovative drugs and high-barrier complex preparations, continuously promoting the progress of multiple research projects, further expanding the diversified product matrix and rich R&D drug pipeline.
Besides With the TG-1000 drug nearing market launch, HealthGen also reached three major strategic collaborations in the respiratory system field, focusing on asthma and chronic obstructive pulmonary disease (COPD), in the first quarter of this year.
In January, HealthGen reached strategic collaborations with Quansin Bio for the anti-TSLP monoclonal antibody injection (QX008N) and with Boan Bio for the long-acting anti-IL-4Rα monoclonal antibody injection (BA2101). Just two months later, HealthGen introduced a small molecule inhibitor from Bayer, a leading global multinational company, expanding its respiratory pipeline from injections to oral medications.
In addition to last year's introduction of the LABA+LAMA dual-target new drug DBM-1152A, HealthGen's innovative drug layout in the respiratory field is particularly eye-catching. If the subsequent R&D of related drugs progresses smoothly, it will comprehensively consolidate the company's competitive advantage as a leader in respiratory preparations.
Meanwhile, HealthGen also introduced the analgesic drug FZ008-145, enriching the company's R&D layout in other areas. This drug is the world's top three and China's first highly selective second-generation Nav1.8 inhibitor, with the advantages of strong and non-addictive analgesia. It was approved for clinical trials in January this year.
In addition, in terms of R&D of high-barrier complex preparations, several projects of HealthGen have also progressed smoothly. Among them, Formoterol Fumarate Inhalation Solution, Long-Chain Fat Emulsion Injection ( OO), and Tocilizumab Injection have been successfully approved for marketing; the Salmeterol/Fluticasone Propionate inhalation powder has completed Phase III clinical trials, and HealthGen is also the first company in China to submit and receive approval for the listing application of this product after the release of new regulations.
Deepening the internationalization strategic layout Towards Big Pharma at full speed
In recent years, HealthGen has adhered to the two major development frameworks of "innovation" and "internationalization", deeply integrating the overall situation of "bringing in" and "going out". While continuously improving the R&D system of the innovative drug pipeline, it is also actively carrying out innovative business cooperation models in the global market, constantly striving to become a top Chinese Big Pharma.
In 2023, HealthGen continued to promote the export of raw materials and the overseas planning of key products, achieving continuous expansion of its overseas territory. Overseas revenue reached 2.584 billion yuan, accounting for 15.64% of the company's main business income.
Currently, HealthGen's products have been exported to more than 80 countries and regions in Asia, Europe, North America, and Africa, and is actively promoting the international registration and certification of its products. By the end of 2023, HealthGen had 18 raw materials and intermediates that had passed international certification on-site inspections and obtained 35 international certification certificates with valid periods.
Based on its existing advantages in raw material exports, HealthGen is actively promoting the overseas planning and strategy of key preparation products, continuously promoting the sales and registration of its respiratory, assisted reproductive, digestive, mental, and anti-infective products in countries such as Pakistan, Indonesia, the Philippines, and Vietnam.
According to publicly available information, HealthGen's chemical preparation products have been approved for registration in overseas markets 4 times and 14 new registrations have been submitted. Among them, the compound ipratropium bromide solution completed registration review in the Philippines and obtained a registration certificate in January 2024; the salbutamol hydrochloride nebulization solution submitted a registration application in Macao and obtained a registration certificate in February 2024; and the ceftriaxone sodium for injection has submitted a registration application to the United States.
In addition to the continuous expansion of the "going out" map, HealthGen is also continuously deepening its "bringing in" strategy, including successfully introducing from overseas the anti-influenza drug TG-1000, innovative drugs in the digestive tract field, potassium-competitive acid blockers (P-CAB), and oral drugs for chronic obstructive pulmonary disease (COPD).
This year March's strategic cooperation with Bayer Group on small molecule inhibitors marks the first time HealthGen has introduced an innovative drug pipeline from a leading global multinational company, which has profound significance for the advancement of the company's internationalization strategic layout.
In 2024, with "innovative drugs" being collectively written into the government work report for the first time, the National Medical Products Administration also stated that it would actively promote the research and development and listing of innovative drugs and high-end medical equipment. "Innovative drugs" have become a key industry buzzword and have ushered in a new development period with policy support.
HealthGen seized the opportunity for industry development by "self-research" and "introduction", deepening the layout of innovative drugs, achieving horizontal layout from the respiratory field to the analgesic field, and vertical expansion of the respiratory pipeline from injection to oral drugs, continuously deepening the company's innovative foundation.
At the same time, in response to the national "3060 dual-carbon goals", HealthGen actively promotes green production, obtains "national-level green factory" certification, and makes positive efforts in social responsibility, promoting the implementation of inclusive chronic disease prevention and control public welfare projects to support rural revitalization and help chronic disease patients in remote areas improve their quality of life.
In the future, HealthGen will continue to firmly grasp the two major development themes of "innovation" and "internationalization", implementing the dual-wheel drive development strategy of "innovative drugs + high-barrier complex preparations", and making every effort to accelerate the progress of innovative research and development and the commercialization of new products, promoting the company's high-quality and sustainable development.
This article is from: China Daily Website